Miсhelle Keller is heading a team of scientific business developers at Deep Longevity, an artificial intelligence (AI) company developing and utilizing deep learning systems for aging and longevity research and a pioneer in deep biomarkers of aging. As a young aspiring scientist in the field of bioinformatics, Michelle was always fascinated by the idea of increasing human lifespan beyond limits. She started her career as a research scientist at Insilico Medicine, a leader in the field of next-generation AI solutions for drug discovery and development. In 2020, when Insilico announced Deep Longevity as a spin-off focusing on longevity extension, Michelle chose to focus on biomarkers of aging and joined the newly-founded company as a research scientist.

At Deep Longevity she invented and implemented several critical applications of AI-based biomarkers of aging in clinical practice and developed the research and commercial relationships with the leading longevity clinics including Human Longevity, Inc, Hooke London, Epigenetic House, Life Clinic Hong Kong, Boulder Longevity, and many others.